Jessica Perhanidis - GlaxoSmithKline

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Cervicovaginal Metabolome is Predictive of Endometrial Cancer and Tumor Characteristics and Leveraged for Risk Stratification

Dana Chase, Soham Shukla, Julia Moore, Tirza Boyle,Jonathan Lim,Jessica Perhanidis, Jean Hurteau,Jeanne Schilder

Gynecologic Oncology (2024)

引用0浏览0引用

An Emulated Target Trial Case Study of Real-World Overall Survival with Second-Line Maintenance Niraparib Versus Active Surveillance in Patients with Recurrent Ovarian Cancer

Jessica A. Perhanidis,Linda Kalilani,Nicole M. Zimmerman,Amanda Golembesky

PHARMACOEPIDEMIOLOGY AND DRUG SAFETYno. 9 (2024)

引用0浏览0WOS引用

Development and Application of an Epithelial Ovarian Cancer-Specific Line of Therapy Algorithm Using Real-World Data

Connor Sweetnam,Tirza Areli Calderon Boyle, Sara Burns,Jessica Perhanidis,Matthew Rioth,Rayna K. Matsuno

CANCER RESEARCH（2024）

引用0浏览0引用

Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: the PRED1CT Real-World Study

Dana M. Chase,Soham Shukla, Julia Moore,Tirza Areli Calderón Boyle,Jonathan Lim,Jessica Perhanidis,Jean A. Hurteau,Jeanne M. Schilder

Oncology and Therapypp.1-9, (2024)

引用0浏览0WOS引用

197 What is the real-world risk of MDS/AML and other secondary primary malignancies in patients with epithelial ovarian cancer treated with niraparib maintenance treatment? Interim results from a regulatory safety study

Stefan Kommoss, Giulia Tasca,Tirza Areli Calderón Boyle,Amanda Golembesky,Jeanne M Schilder, Izabela A Malinowska, Guilan Ye, Judi Kuplast,Jessica Perhanidis, Zoe Zeliku, Constanza Maximiano Alonso, Maurice Van Der Vorst

Poster and E-Posters (2024)

引用0浏览0引用

Cytochrome P450 Inhibitor/inducer Treatment Patterns among Patients in the United States with Advanced Ovarian Cancer Who Were Prescribed or Were Eligible for Poly(adenosine Diphosphate [Adp]-Ribose) Polymerase Inhibitors in the First-Line Maintenance Setting

Bobbie J. Rimel,Dana M. Chase,Jessica Perhanidis, Armen A. Ghazarian,Ella Xiaoyan Du,Travis Wang,Jinlin Song,Amanda K. Golembesky,Jean A. Hurteau,Linda Kalilani,Ritu Salani,Bradley J. Monk

Gynecologic Oncology Reports (2024): 101332-101332

引用0浏览0WOS引用

Association of Multiple High-Risk Factors on Observed Outcomes in Real-World Patients With Advanced Ovarian Cancer Treated With First-Line Therapy

Dana Chase,Jessica Perhanidis,Divya Gupta,Linda Kalilani,Amanda Golembesky,Antonio González-Martín

JCO clinical cancer informatics（2023）

引用0浏览0WOS引用

Real-world (RW) use of niraparib (Nir) monotherapy (mono) as first-line (1L) switch maintenance (1LSM) therapy following chemotherapy (CT) plus bevacizumab (bev) induction treatment in patients (pts) with epithelial ovarian cancer (EOC) in the SW1TCH study

B.J. Rimel,Tirza Areli Calderón Boyle,Jessica Perhanidis, Stacey Burns, Jormay Lim, John D. Hartman,Linda Kalilani,Jeanne M. Schilder,Jean Hurteau,Amanda Golembesky

JCO oncology practiceno. 11_suppl (2023): 536-536

引用0浏览0引用

Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression Who Received Maintenance Therapy or Active Surveillance

Dana Chase,Jessica Perhanidis,Divya Gupta,Linda Kalilani,Amanda Golembesky,Antonio González-Martín

Oncology and therapyno. 2 (2023): 245-261

引用0浏览0引用

Cytochrome P450 Inhibiting/inducing Medication Use among Patients with Advanced Ovarian Cancer Who Receive or Are Eligible for Poly (Adp-Ribose) Polymerase Inhibitors As First Line Maintenance Therapy (2200)

Dana Chase,Bobbie Rimel,Jessica Perhanidis, Armen Ghazarian,Ella Xiaoyan Du,Travis Wang,Jinlin Song,Amanda Golembesky,Jean Hurteau,Ritu Salani,Bradley Monk

Gynecologic oncology (2023): S257-S257

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn